Article
Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients
Registro en:
CAHN, Pedro. et al. Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients. AIDS, v. 25, p. 929–939, 2011.
0269-9370
10.1097/QAD.0b013e328345ee95
Autor
Cahn, Pedro
Fourie, Jan
Grinsztejn, Beatriz
Hodder, Sally
Molina, Jean-Michel
Ruxrungtham, Kiat
Workman, Cassy
Van De Casteele, Tom
De Doncker, Piet
Lathouwers, Erkki
Tomaka, Frank
Resumen
ODIN (Once-daily Darunavir In treatment-experieNced patients) was a phase III, 48-week, open-label study comparing once-daily vs. twice-daily darunavir/ritonavir (DRV/r) in treatment-experienced patients with no DRV resistance-associated mutations (RAMs) at screening. 2028-08-30